ReviewAnticholinergic agents in asthma and COPD
Introduction
Although naturally occurring anticholinergic alkaloids such as atropine and scopolamine have been used in traditional medical cultures for many years, these agents are well absorbed into the systemic circulation and thus have multiple systemic side-effects that limit their clinical usefulness. The discovery that synthetic quaternary congeners of atropine were very poorly absorbed but retained topical anticholinergic activity enabled the development of analogues of atropine such as ipratropium, oxitropium, and tiotropium bromides for clinical use as inhaled bronchodilators. In the last 2 decades, these agents have become important agents in the routine treatment of COPD but also for asthma in certain circumstances.
Section snippets
Available agents
In most countries, ipratropium bromide is available as a metered-dose inhaler, as a dry powder inhalation, and as a nebulizable solution as Atrovent®. Because the original dose of ipratropium, 40 μg, is suboptimal for COPD (Gross et al., 1989), a double strength metered-dose inhaler form, Atrovent forte®, is also available in many countries outside the USA. Fixed combinations of ipratropium with albuterol (salbutamol) are also available in metered-dose inhaler form as Combivent® and in
Stable COPD
The major clinical use of inhaled anticholinergic agents is for the routine treatment of stable COPD. Several large multi-center long-term clinical studies in the 1980s compared ipratropium metered-dose inhaler with a β-adrenoreceptor agonist metered-dose inhaler. These uniformly showed that the increase in Forced Expired Volume in 1 s (FEV1), the primary outcome of the studies, was at least as great and as prolonged with ipratropium as with a conventional β-adrenoreceptor agonist and sometimes
Side-effects and adverse events
Being very poorly absorbed, currently approved inhaled anticholinergic agents have a very wide therapeutic margin and are very well tolerated, even in rare instances when massive doses have accidentally been given (Gross and Skorodin, 1985). In normal clinical use, dryness of the mouth is a common side effect of all agents in this class but is rarely sufficiently severe for the patient to discontinue use. Bad taste is an occasional complaint, as is a brief coughing spell shortly after
References (33)
- et al.
Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study
JAMA
(1994) - et al.
Preservatives in nebulizer solutions: risks without benefit
Pharmacotherapy
(1998) - et al.
Possible association of benzalkonium chloride in nebulizer solutions with respiratory arrest
Ann. Pharmacother.
(1992) - et al.
Assessment of the clinical usefulness of nebulised ipratropium bromide in patients with chronic airflow limitation
Thorax
(1984) - et al.
Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD
Thorax
(2003) - et al.
A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease
Eur. Respir. J.
(2002) - et al.
Standards for the diagnosis and treatment of patients with COPD; a summary of the ATS/ERS position paper
Eur. Respir. J.
(2004) The protective effect of inhaled Sch1000 MDI on bronchoconstriction induced by serotonin, histamine, acetylcholine and propanaolol
Postgrad. Med. J.
(1975)- et al.
Ba 679 BR, a novel long-acting anticholinergic bronchodilator
Life Sci.
(1993) - GOLD, The Global Initiative for Chronic Obstructive Lung Disease, 2003. Global strategy for the diagnosis, management,...
Ipratropium bromide
N. Engl. J. Med.
Tiotropium bromide
Chest
Anticholinergic, antimuscarinic bronchodilators
Am. Rev. Respir. Dis.
Role of the parasympathetic system in airway obstruction due to emphysema
N. Engl. J. Med.
Massive overdose of atropine methonitrate with only slight untoward effects
Lancet
Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease. A three-center study
Am. Rev. Respir. Dis.
Cited by (133)
Optimizing asthma management: Role of long-acting muscarinic antagonists
2022, Journal of Allergy and Clinical ImmunologyEvaluation of bronchodialatory and antimicrobial activities of Otostegia fruticosa: A multi-mechanistic approach
2020, Saudi Pharmaceutical JournalCitation Excerpt :Since cAMP levels are increased when PDE enzyme is inhibited in the tissues (Harris and Connell, 1989), therefore, we conclude that PDE-inhibitory-like components co-exist in the bronchodilatory effect of Of.Cr in combination with anticholinergic and CCB. The significance of muscarinic receptor antagonists and PDE inhibitors are well-established facts in asthma (Barnes, 2006), despite their major limitation as that both produce cardiac stimulation (Nawarth, 1981; Nicholas, 2006). Interestingly, studies show the possible potential clinical implications of CCBs in bronchoconstriction (Twiss et al., 2002) parallel to its cardiac-inhibitory actions (Billman, 1992).
Spiral mouthpiece design in a dry powder inhaler to improve aerosolization
2018, International Journal of PharmaceuticsAutonomic nervous system pharmacology
2018, Pharmacology and Physiology for Anesthesia: Foundations and Clinical ApplicationEffects of tiotropium on lung function in current smokers and never smokers with bronchial asthma
2017, Pulmonary Pharmacology and TherapeuticsCitation Excerpt :In this study, we also found that the degree of improvement in FEV1 and PEFR was greater in the ACOS group than in the group with pure asthma without emphysematous changes. Such a difference in efficacy between the study groups could be explained by the presence of COPD as co-morbidity, as previous studies have shown that muscarinic antagonists provide an equal or greater bronchodilatory effect than β2-adrenoreceptor agonists in COPD [22]. However, we cannot exclude the possibility that the difference in smoking status in the study groups can lead to a difference in changes of lung function, as subjects we recruited consisted of 18 nonsmoker asthmatics without emphysematous changes and 18 smokers with ACOS.
Detection of doping peptides and basic drugs in equine urine using liquid chromatography–mass spectrometry
2024, Drug Testing and Analysis